Alex
At Best Startup Canada we track over 100,000 Canadian startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top British Columbia based VP’ operating in the Medical space. If you think a VP’ is missing from this list, feel free to contact our editor on editor@beststartup.ca.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Surjit Dixit
Vice President Technology of Zymeworks
Dr. Dixit is Zymeworks’ Chief Technology Officer, responsible for the implementation of novel algorithms and advancement of the ZymeCAD™ platform. Prior to joining Zymeworks, Dr. Dixit was the coordinator of Computational Molecular Biophysics at Weselyan University, Connecticut, USA, where he was instrumental in the development of novel methods for management and mining of high throughput molecular dynamics simulation data.
Follow Surjit Dixit:
About Zymeworks: Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Neil Klompas
Chief Financial Officer & EVP Business Operations of Zymeworks
Mr. Klompas is Zymeworks’ Chief Financial Officer, and brings over 20 years of healthcare and biotechnology experience to Zymeworks’ management team. Additionally, in conjunction with the CEO, he manages Zymeworks’ corporate growth initiatives including corporate alliances, licensing and partnerships. Prior to joining Zymeworks he worked with KPMG LLP in Canada and the US, most recently with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton NJ, where he advised on numerous transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice in the fields of assurance, valuations and taxation. Mr. Klompas is a Chartered Accountant and is a member of the institute of CA’s of British Columbia.
Follow Neil Klompas:
About Zymeworks: Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Jennifer Kaufman-Shaw
VP Intellectual Property and Legal Affairs of Zymeworks
Kaufman-Shaw joined Zymeworks in August 2014 and currently serves as our Vice President, Intellectual Property. Dr. Kaufman-Shaw brings with her over 20 years of intellectual property management, strategy and execution experience to the management team. Dr. Kaufman-Shaw is responsible for our intellectual property portfolio and global patent strategy, as well as supporting our therapeutics and platform licensing activities. Prior to joining Zymeworks, Dr. Kaufman-Shaw was a Co-Founder of ImStar Therapeutics Inc., a biotechnology company, and also served as its Vice President, Intellectual Property and Legal Affairs from its founding in May 2012 to July 2014. She also served as a Vice President at the biotechnology company Sirius Genomics Inc. (from August 2007 to May 2012), and held various senior roles at QLT Inc. (from July 1997 to July 2007) including, most recently, Vice President, Patent Counsel (from 2005 to 2007), where she was responsible for developing and executing intellectual property strategies. Dr. Kaufman-Shaw is admitted to both the Alberta and British Columbia Bars and holds a Bachelor of Laws (LL.B.) and a doctorate in Biochemistry from the University of Alberta. She is currently serving as a member of the board of directors of MRM Proteomics Inc., a proteomics services and kit provider.
Follow Jennifer Kaufman-Shaw:
About Zymeworks: Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Salmaan Ahmed
VP Software and Founder of Onc.AI
Salmaan Ahmed currently works as Vice President of Software and Founder at Onc.AI.
Follow Salmaan Ahmed:
About Onc.AI: Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics.
Mark Ross
Co-Founder and VP of Mindful Garden
Mark Ross currently works as Co-Founder and Vice President at Mindful Health. He was a Vice President for Accounts and Business Development at Switch United.
Follow Mark Ross:
About Mindful Garden: Mindful Garden develops a behaviour modification platform to de-escalate anxiety and aggression of patients with chronic disease.
Brian Kwok
VP Product Development of Fusion Genomics Corporation
Follow Brian Kwok:
About Fusion Genomics Corporation: Fusion Genomics develops highly sensitive and massively multiplex DNA/RNA sequencing based diagnostics for infectious diseases.
Nicole Ranger
Vice President of Engineering & Product Development of Pyng Medical
A Professional Engineer, Nicole brings over 17 years of experience in managing and developing product lines from concept to market, with over 9 years in the medical device industry. Since joining Pyng Medical, Nicole has led product development and enhancement projects, contributing significantly to Pyng Medical’s first reaching profitability. Prior to joining Pyng Medical, Nicole held R&D, engineering, project and product management roles in the medical device, sports equipment and bioengineer industries. She is responsible for developing over a dozen products now in the marketplace and is named in four patents. Nicole holds a Bachelor of Applied Science (Mechanical Engineering) from the University of Toronto as well as a Bachelor of Science (Honours Kinesiology) from the University of Waterloo.
Follow Nicole Ranger:
About Pyng Medical: Pyng Medical develops trauma and resuscitation products for the health care industry.
Iman Mansoor
Vice President of Engineering and Innovation of Microdermics
Iman has been involved in research and development of microneedles for more than 8 years. He received his bachelor’s degree in mechanical engineering (mechatronics option) in 2007 and his master’s and Ph.D. degrees in electrical engineering in 2009 and 2014, respectively, from the University of British Columbia (UBC), Vancouver, BC, Canada. He also received a sub-specialization certificate in Engineering Management and Technology Entrepreneurship in 2013 from UBC. Iman’s graduate research was in the field of Microelectromechanical Systems (MEMS) and mainly focused on process development and characterization of microneedle devices for intradermal drug delivery and biosensing applications. He currently holds a patent on the microneedle fabrication process developed during his graduate research. Since 2014, Iman has worked as Systems Consultant and Product Development Specialist in major engineering companies and has completed several successfully-commercialized projects. During this period, he has also been active in further development and commercialization of microneedle devices.
Follow Iman Mansoor:
About Microdermics: Unlocking continuous biochemical data for clinically relevant insights.
Sahan Ranamukhaarachchi
Co-founder, Vice President of Research & Development of Microdermics
Follow Sahan Ranamukhaarachchi:
About Microdermics: Unlocking continuous biochemical data for clinically relevant insights.
Michael Lyle
Vice President – Research and Development of Welichem Biotech
Dr. Lyle joined the company in 2006 as a medicinal chemist working on our early stage drug development programs in inflammatory diseases and cancer. From there he became the Head of Chemistry in 2008 and the VP of Research and Development in 2010. Dr. Lyle played an integral role in the development of WBI1001 and these efforts ultimately culminated in the $230M acquisition of WBI1001 by GSK in July 2012. Dr. Lyle holds a PhD in Chemistry from Simon Fraser University (SFU) and has authored numerous peer-reviewed scientific publications and patents.
Follow Michael Lyle:
About Welichem Biotech: Welichem Biotech is a development stage biotechnology company, engages in the discovery and development of therapeutic drugs.
Ryan Anderson
Vice President of Sales & Marketing of OneTeamVisi
Ryan Anderson is a master of relationships with more than 10 years of experience in the direct sales industry. Ryan was exposed to the direct sales industry at a young age, having his mother as a major influence in his life. He has shared the dream and value of entrepreneurship in 22 international markets while serving in various sales, management, and executive roles with some of the biggest companies in the direct sales industry. He has a deep passion for helping others reach their potential and grow into the greatness they were born with. Ryan graduated from the University of Phoenix with a B.S. in Business Management and Marketing.
Follow Ryan Anderson:
About OneTeamVisi: Centered on the powerful benefits of Scandinavian nature including the Arctic Cloudberry.
Bruce Reese
Vice President of Finance of Apteryx Imaging
Follow Bruce Reese:
About Apteryx Imaging: Apteryx Imaging develops tissue fluorescence visualization technologies.
GIPHY App Key not set. Please check settings